ADEPT

ADEPT (Antibody-directed enzyme prodrug therapy)^[1] is a strategy to overcome the problems of lack of tumor selectivity. An antibody designed/developed against a tumor antigen is linked to an enzyme and injected to the blood, resulting in selective binding of the enzyme in the tumor. When the discrimination between tumor and normal tissue enzyme levels is sufficient, a prodrug is administrated into the blood circultion, which is converted to an active cytotoxic drug by the enzyme, only within the tumor. Selectivity is achieved by the tumor specificity of the antibody and by delaying prodrug administration until there is a large differential between tumor and normal tissue enzyme levels.

Additional recommended knowledge

Daily Visual Balance Check

Weighing the right way

How to ensure accurate weighing results every day?

ADEPT has shown antitumor activity in animal tumor models of human choriocarcinoma and colonic and breast carcinoma.

ADEPT history

The first pilot-scale clinical trial of ADEPT was carried out at Charing Cross Hospital, London, using an anti-CEA F(ab′)2 antibody conjugated to the bacterial enzyme carboxypeptidase G2 (CPG2)^[2].

The antibody used in the first ADEPT clinical trial was of murine origin and the enzyme was bacterial. Host antibodies to both components of the AEC were present in the blood of all non-immunosuppressed patients by day 10 after AEC infusion ^[3]. Several patients received cyclosporin since it had been shown in rabbits that this could delay the appearance of host antibodies to soluble proteins ^[4].

A subsequent, small-scale trial at the Royal Free Hospital, London, used the same agents as in the Charing Cross Hospital trial but the protocol was modified to provide additional pharmacokinetic data and most patients received only a single course of treatment ^[5].

Other versions of directed enzyme prodrug therapy (DEPT)

There are several other strategies to use prodrug/enzyme systems for cancer therapy, including gene-directed enzyme prodrug therapy (GDEPT), virus-directed enzyme prodrug therapy (VDEPT), PDEPT (Polymer-Directed Enzyme Prodrug Therapy), LEAPT (Lectin-directed enzyme-activated prodrug therapy)^[6][7], and CDEPT^[8] (Clostridial-directed enzyme prodrug therapy).

References

1. ^ Bagshawe KD. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Rev Anticancer Ther. 2006; 6(10): 1421-1431.Entrez PubMed 17069527
2. ^ KD Bagshawe, SK Sharma, CJ Springer and P Antoniw, Antibody directed enzyme prodrug therapy (ADEPT): a pilot scale clinical trial. Tumor Targeting 1 (1995) 17–29.
3. ^ KD Bagshawe and SK Sharma, Cyclosporin delays host immune response to antibody enzyme conjugate in ADEPT. Transplant Proc 28 (1996), 3156–3158. Entrez PubMed 8962223
4. ^ JA Ledermann, RHJ Begent and KD Bagshawe, Cyclosporin A prevents the anti murine antibody response to a monoclonal antibody in rabbits. Br J Cancer 58 (1988), 562–566.
5. ^ KD Bagshawe and M Napier, Early clinical studies with ADEPT. In: RG Melton and RJ Knox Editors, Enzyme-Prodrug Strategies for Cancer Therapy Kluwer Academic, London (1999), 199–207.
6. ^ Silva AT, Chung MC, Castro LF, Guido RV, Ferreira EI. Advances in prodrug design. Mini Rev Med Chem. 5 (2005) 893-914.Entrez PubMed 16250833
7. ^ Xu G, McLeod HL. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res. 7 (2001) 3314-24.Entrez PubMed 11705842
8. ^ Minton NP. Clostridia in cancer therapy. Nat Rev Microbiol. 2003;1:237–42.Entrez PubMed 15035028